

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

213876Orig1s000

Trade Name: ALKINDI SPINKLE

Generic or Proper Name: hydrocortisone oral granules

Sponsor: Diurnal Limited

Approval Date: September 9, 2020

Indication: For the use of Alkindi Sprinkle (hydrocortisone) oral granules as a replacement therapy in pediatric patients with adrenocortical insufficiency.

CENTER FOR DRUG EVALUATION AND RESEARCH

213876Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X



NDA 213876

NDA APPROVAL

Covance, U.S. Agent for Diurnal Limited
Attention: Christina Bucciero
Manager, Program Management
100 Mettlers Road
Somerset, NJ 08873

Dear Ms. Bucciero:

Please refer to your new drug application (NDA) dated and received November 29, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Alkindi Sprinkle (hydrocortisone) oral granules.

This new drug application provides for the use of Alkindi Sprinkle (hydrocortisone) oral granules as replacement therapy in pediatric patients with adrenocortical insufficiency.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on August 10, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 213876.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

The dating period for Alkindi Sprinkle shall be 36 months from the date of manufacture when stored at 20°C to 25°C. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) .

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

*Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

We also remind you of your agreement to conduct enhanced pharmacovigilance for all cases of choking, aspiration, and incorrect drug administration technique reported with Alkindi Sprinkle (hydrocortisone) oral granules for a period of 3 years from the date of this letter. Submit all cases of choking, aspiration, and incorrect drug administration technique as 15-day Alert reports (as described under 21 CFR 314.80(c)(1)), and provide detailed analyses of events of choking, aspiration, and incorrect drug administration technique reported from clinical studies and post-marketing reports in your periodic safety report (i.e., the Periodic Adverse Drug Experience Report [PADER] required under 21 CFR 314.80(c)(2) or the ICH E2C Periodic Benefit-Risk Evaluation Report [PBRER] format). These analyses should show cumulative data relative to the date of approval of Alkindi Sprinkle (hydrocortisone) oral granules as well as relative to prior periodic safety reports. Medical literature reviews for case reports/case series of choking, aspiration, and incorrect drug administration technique reported with Alkindi Sprinkle (hydrocortisone) oral granules should also be provided in the periodic safety report.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, call Jennifer Johnson, Regulatory Health Project Manager, at (301) 796-2194.

Sincerely,

{See appended electronic signature page}

Theresa E. Kehoe, M.D.
Director (Acting)
Division of General Endocrinology
Office of Cardiology, Hematology, Endocrinology, and
Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
09/29/2020 04:25:39 PM